Summary
The progress in the therapy of the myelodysplastic syndromes has been far from spectacular during recent years. No currently available treatment has been shown to be consistently effective in producing sustained improvement in hematopoiesis or in delaying leukemic evolution. With regard to both quantity and quality of life, no other treatment has been proven superior to classical supportive treatment, with the possible exception of bone marrow transplantation in younger patients. While in selected cases anecdotal successes have been noted with the use of hormonal therapy, some differentiation inducers, e.g. vitamin A- en D-analogues, have not hold their promises in placebo controlled trials. Attempts to induce complete remissions in MDS with antileukemic treatment have usually been unsuccessful. Toxicity is substantial and a considerable proportion of patients fare worse with chemotherapy than with standard supportive care. Recently, a flood of reports has appeared on the use of biological response modifiers e.g. cytokines and growth factors in the treatment of MDS. Perhaps some of these hold promises for a new era in MDS, but the data are preliminary and no follow-up on long term survival is at hand.
Similar content being viewed by others
References
Appelbaum FR, Storb R, Ramberg RE (1984) Allogeneic marrow transplantation in the treatment of preleukemia. Ann Intern Med 100: 689–693
Armitage JO, Dick FR, Needleman SW, Burns CP (1981) Effect of chemotherapy for the dysmyelopoietic syndrome. Cancer Treat Rep 65: 601–605
Badhuri S, Kubanek B, Heit W, Pflieger H, Kurrle E, Fliedner TM, Heimpel H (1979) A case of preleukemia — reconstitution of normal marrow function after bone marrow transplantation (BMT) from identical twin. Blut 38: 145–149
Bagby GC, Gabourel JD, Linman JW (1980) Glucocorticoid therapy in the preleukemia syndrome. Ann Intern Med 92: 55–58
Belanger R, Gyger M, Perreault C, Bonny Y, St-Louis J (1988) Bone marrow transplantation for myelodysplastic syndromes. Br J Haematol 69: 29–33
Bennet JM, Catovsky D, Daniel M-T (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51: 189–199
Bennet JM, Catovsky D, Daniel M-T (1985) Proposed revised criteria for the classification of acute myeloid leukemia. Ann Intern Med 103: 626–629
Boogaerts MA, Nelissen V, Roelant C, Goossens W (1983) Blood neutrophil function in primary myelodysplastic syndromes. Br J Haematol 55: 217–227
Clark RE, Ismail SAD, Jacobs A, Payne H, Smith SA (1987) A randomized trial of 13-cis-retinoic acid with or without cytosine arabinoside in patients with the myelodysplastic syndrome. Br J Haematol 66: 77–83
Galvani DW, Cawley JC, Nethersell A, Bottemley JM (1987) α-interferon in myelodysplasia. Br J Haematol 66: 145–146
Gold EJ, Mertelsmann RM, Itri LM, Gee T, Arlin Z, Kempin S, Clarkson B, Moore MA (1983) Phase I clinical trial of 13-cis-retinoic acid in myelodysplastic syndromes. Cancer Treat Rep 67: 981–986
Hoelzer D, Ganser A, Völkers B, Walther F, Becker R, Bergman D (1988) Proceedings Int Soc Haematology, Eds. ISH, Milan: 6 (abstract)
Koeffler HP (1983) Induction of differentiation of human acute myelogenous leukemia cells: therapeutic implications. Blood 62: 709–721
Layton DM, Mufti GJ (1988) Loss of ras oncogene mutation in a myelodysplastic syndrome after low dose cytarabine therapy. N Engl J Med 318: 1468
Levine EG, Bloomfield CD (1986) Secondary Myelodysplastic Syndromes and Leukaemias. Clin Haematol 15: 1037–1080
Linman JW, Bagby GC (1978) The preleukemic syndrome (hematopoietic dysplasia). Cancer 42: 854–864
Mehta AB, Kumaran TO, Marsh GW, McCarthy DM (1984) Treatment of advanced myelodysplastic syndrome with alfacalcidol. Lancet II: 761
Michels SD, McKenna RW, Arthur DC, Brunning RD (1985) Therapy related acute myeloid leukemia and myelodysplastic syndrome: a clinical and morphologic study of 65 cases. Blood 65: 1364–1372
Mufti GJ, Stevens JR, Oscier DG (1985) Myelodysplastic syndromes: a scoring system with prognostic significance. Br J Haematol 59: 425–433
Najean Y, Pecking A (1979) Refractory anaemia with excess of blasts: prognostic factors and effect of treatment with androgens or cytosine arabinoside. Results of a prospective trial in 58 patients. Cancer 44: 1976–1982
O'Donnell MR, Nademanee AP, Snyder DS, Schmidt GM, Parker PM, Bierman PJ, Fahey JL, Stein AS, Krance RA, Stock AD (1987) Bone marrow transplantation for myelodysplastic and myeloproliferative syndromes. J Clin Oncol 5: 1822–1826
Polli EE (1988) Clinical study with human recombinant gamma-interferon in patients with high risk myelodysplastic syndromes. Proceedings Int Soc Haematology, Eds. ISH, Milan, 264–266
Spriggs DR, Stone RM, Kufe DW (1986) The treatment of the myelodysplastic syndromes. Clin Haematol 15: 1081–1107
Talpaz M, Kantarjian HM, Mc Credic K, Trujillo JM, Keating MJ, Guttermann JV (1986) Hematologic remission and cytogenetic improvement induced by recombinant alfainterferon in chronic myelogenous leukemia. N Engl J Med 314: 1065–1069
Tricot G, Boogaerts MA (1986) The role of aggressive chemotherapy in the treatment of the myelodysplastic syndromes. Br J Haematol 63: 477–483
Vadjan Raj S, Keating M, Le Maistre A, Hittelman WN, Mr Credeie K, Trujillo JM, Broxmyer HE, Henney C, Guttermann JU (1987) Effects of recombinant human GM-CSF in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1552
Varela BL, Chuang C, Woll JE (1985) Modifications in the classification of primary myelodysplastic syndrome: the addition of a scoring system. Hematol Oncol 3: 55–63
Verwilghen RL, Boogaerts MA (1987) The myelodysplastic syndromes. Blood Rev 1: 3–10
Weisdorf DJ, Oken MM, Johnson GL (1983) Chronic myelodysplastic syndromes: short survival with or without evolution to acute leukemia. Br J Haematol 55: 691–700
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Boogaerts, M.A. Progress in the therapy of myelodysplastic syndromes. Blut 58, 265–270 (1989). https://doi.org/10.1007/BF00320163
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00320163